Disease
Thyroid cancer甲状腺癌
ICD-10: C73 — Malignant neoplasm of thyroid gland
Key figures
Published values only. Every tile opens the section that carries its source, its year and its caliber.
Disease details
- Standard Chinese name
- 甲状腺癌
- English name
- Malignant neoplasm of thyroid gland
Values written in Chinese are quoted as published by the source.
Also known as
- PTC
- Papillary thyroid carcinoma
Treatment cost ranges
Every range below is published on one billing basis: Pre-reimbursement 医保报销前. The sources publish no post-reimbursement figure, so none is shown here.
| Treatment path | Cost range | Price basis | Data year |
|---|---|---|---|
| Surgery 手术 | 16000 – 23000 CNY | Condition package price 病种打包全包价 | 2020–2025 |
| Radiotherapy 放疗 | Not applicable | Not applicable 不适用 | — |
| Chemotherapy 化疗 | Not applicable | Not applicable 不适用 | — |
| Targeted therapy 靶向 | 57000 – 233000 CNY | Per-item price 项目价 | 2025 |
| Immunotherapy 免疫 | Not applicable | Not applicable 不适用 | — |
| Laparoscopic surgery 腔镜手术 | 21700 – 28200 CNY | Average per case (full course) 全病程例均 | 2019–2022 |
The bars share one scale across the rows above: each starts at that row's lower published figure and ends at its upper one. The highest upper figure on this page is 233000 CNY. Each row keeps its own data year and caliber.
6 cost ranges for this condition, each with its source on the row page.
Values written in Chinese are quoted as published by the source.
Five-year survival
5-year survival rate 92.9% 95% CI 92.4–93.3
- Population
- Overall (all stages combined) · Age-standardised relative survival 总体（全分期合并）· 年龄标准化相对生存率
- Period
- 2019–2021
- Publisher
- National Cancer Center 国家癌症中心
- Value nature
- Estimated value (hybrid analysis) 估计值（混合法）
- Registry scope
- 281 population-based cancer registries 281 个肿瘤登记处
- Stage data availability
- Not published
Values written in Chinese are quoted as published by the source.
How to read this figure. It is published for all stages combined, so it is an average over everyone in the national registry data rather than a prognosis for one person. For most cancers, the stage at diagnosis is the strongest single factor behind survival differences: survival is generally higher when the cancer is found at an earlier stage and lower when it is found later. Comparisons between cancers are also shaped by how early or late each one tends to be diagnosed, so a lower figure does not by itself mean worse care.
Hospitals with a published record for this condition
Selected using official public data sources
These hospitals are selected from official public data sources — the Fudan University hospital specialty reputation rankings, the national key clinical specialties list and national clinical research centres — so each line on a card can be checked against its published source. This is not a paid or promoted listing.
How these hospitals were selected
Admission. A hospital is listed for a condition when the specialty that condition is filed under carries at least one of: a place or a nomination in the Fudan University hospital specialty reputation ranking; a national key clinical specialty record at level A, B or C; or a national clinical research centre or a state key laboratory in that specialty. JCI accreditation is shown as a badge; it never decides admission and it never decides order.
Order. Step 1: a Fudan place between 1 and 10 for the specialty. Step 2: another Fudan place, or a nomination. Step 3: a level-A national key clinical specialty. Step 4: a level-B national key clinical specialty. Step 5: a national clinical research centre or a state key laboratory in the specialty, a centre before a laboratory. Step 6: a level-C national key clinical specialty, which is a record we publish without an independent official source and which is therefore listed after the others.
Ties. Within one step: the better Fudan place first, then the stronger key-specialty level (A before B before C), then the province, then the city, then the hospital name - the same province-city-name order the hospital directory uses. At most eight hospitals are listed.
When the list is short. Five hospitals or more: the first eight are listed. Three or four: all of them are listed, and a further fold adds the remaining records up to eight, each carrying its evidence level. One or two: the same, with that fold open and a line stating how many hospitals have a strong public record. None: the page states that no strong public record was found and links to the specialty directory. A place, an institution or a count is never invented to fill the list.
The Fudan rankings are the hospital specialty reputation ranking most widely recognised by Chinese clinicians, published annually by Fudan University's hospital management institute.
-
West China Hospital, Sichuan University四川大学华西医院
National key clinical specialty
- Head and Neck Surgery (level A) https://wcums.scu.edu.cn/kxyan_jiu/gjlczdzk.htm
Also ranked: General Surgery #3, Thoracic Surgery #4, Urology #2 (tied) in the Fudan list.
-
Chongqing General Hospital重庆市人民医院
National key clinical specialty
- Head and Neck Surgery (level A) https://wsjkw.cq.gov.cn/zwgk_242/fdzdgknr/tzgg/gzgs/202412/t20241225_14021980_wap.html
Published research
- The influence of fine-needle aspiration on dual-layer detector spectral CT parameters of papillary thyroid carcinoma: a propensity-match analysis. BMC medical imaging, 2026
PubMed indexes 1 paper on this condition that names this hospital.
Also ranked: Otorhinolaryngology nominated in the Fudan list.
-
XinHua Hospital上海交通大学医学院附属新华医院
National key clinical specialty
- Head and Neck Surgery (level B) https://www.xinhuamed.com.cn/?channel=hot
Published research
- Correction: Crosstalk between abnormal TSHR signaling activation and PTEN/PI3K in the dedifferentiation of thyroid cancer cells. Frontiers in oncology, 2026
PubMed indexes 1 paper on this condition that names this hospital.
-
Shanghai General Hospital上海市第一人民医院
National key clinical specialty
- Head and Neck Surgery (level B) https://www.firsthospital.cn/List/Depart/f0
Published research
- Ultrasound radiomics for preoperative evaluation of Ki-67 proliferation index in papillary thyroid carcinoma. Frontiers in oncology, 2026
PubMed indexes 1 paper on this condition that names this hospital.
Also ranked: Urology nominated, Ophthalmology #8 in the Fudan list.
-
Sichuan Cancer Hospital四川省肿瘤医院
National key clinical specialty
- Head and Neck Surgery (level B) https://www.sichuancancer.org/yygk/yyjs.htm
Also ranked: Medical Oncology #10 in the Fudan list.
-
The Third Affiliated Hospital of Sun Yat-sen University中山大学附属第三医院
National key clinical specialty
- Head and Neck Surgery (level B) https://www.zssy.com.cn/basic/468
Also ranked: Infectious Diseases 传染感染 #10, Nuclear Medicine 核医学 nominated in the Fudan list.
-
Nanjing Drum Tower Hospital南京鼓楼医院（南京大学医学院附属鼓楼医院）
National key clinical specialty
- Head and Neck Surgery (level B) https://www.njglyy.com/zbmz/zbmz2.aspx
-
Tongji Hospital, Tongji Medical College, Huazhong University of Science & Technology华中科技大学同济医学院附属同济医院
National key clinical specialty
- Head and Neck Surgery (level B) https://www.tjh.com.cn/contents/934/27291.html
Also ranked: General Surgery #6, Urology #5, Gynecology #2 in the Fudan list.
Clinical trials (investigational treatments)
In addition to standard care, clinical research studies for Thyroid cancer may currently be open to participants in China. The treatments under study have not been approved by the regulator as standard therapy — they are clinical research, not routine treatment. Each record names the lead investigator and the hospital running the study. If you are interested, contact the hospital to ask about eligibility and choose whether to apply.
-
Study Biochemical, Radiological and Pathological Responses to Neoadjuvant Treatment in Locally Advanced Thyroid Cancer: A Multicenter Study
- Lead investigator
- wenxin zhao · Professor and Chief Surgeon, Department of Thyroid Surgery
- Hospital
- Fujian Medical University Union Hospital
- Status
- Recruiting
- Registry
- NCT07419932
-
Study Humanistic Continuing Care Via WeChat for Patients Undergoing Thermal Ablation of Papillary Thyroid Carcinoma
- Lead investigator
- Ming-an Yu · Head of department of intervention medicine
- Hospital
- China-Japan Friendship Hospital
- Status
- Recruiting
- Registry
- NCT07302672
-
Study A Multicenter, Multi-Cohort, Phase II Study of Sacituzumab Tirumotecan With or Without Tislelizumab in Patients With Advanced Thyroid Cancer
- Lead investigator
- Minghua Ge · Professor
- Hospital
- Zhejiang Provincial People's Hospital
- Status
- Recruiting
- Registry
- NCT07068542
-
Study Safety and Efficacy of Recombinant Human Thyroid Stimulating Hormone for Adjuvant Diagnosis in Patients With Locally Advanced/Metastatic Differentiated Thyroid Cancer
- Lead investigator
- Feng Wang · Director of nuclear medicine department
- Hospital
- First Affiliated Hospital of Guangzhou Medical University
- Status
- Recruiting
- Registry
- NCT06431620
-
Study Trophoblast Cell-Surface Antigen 2 (Trop-2) Targeted PET/CT in Recurrent and Metastatic Thyroid Cancer and Compared With 68Ga-FAPI PET/CT
- Hospital
- First Affiliated Hospital of Guangzhou Medical University
- Status
- Recruiting
- Registry
- NCT07753499
5 more registered studies
-
Study A Comparative Study of Preoperative and Intraoperative Carbon Nanoparticles Injection in Patients Undergoing Thyroid Cancer Surgery
- Hospital
- The Second Affiliated Hospital of Xi'an Jiaotong University
- Status
- Recruiting
- Registry
- NCT06791005
-
Study Prospective Cohort Study on Clinical Characteristics of Thyroid Cancer in Different Iodine Status Areas
- Lead investigator
- Hai-qing Zhang · Chief physician
- Hospital
- Shandong Provincial Hospital
- Status
- Recruiting
- Registry
- NCT06623500
-
Study Impact of Thyroid Treatment on Ovarian Function and Pregnancy Outcomes in Women with Differentiated Thyroid Cancer: a Prospective Cohort Study
- Hospital
- Zhejiang Provincial People's Hospital
- Status
- Not yet recruiting
- Registry
- NCT06845098
-
Study A Multicenter Prospective-Retrospective Real-World Study Evaluating Conversion-to-Surgery and Survival After Genotype-Matched Neoadjuvant Systemic Therapy in Locally Advanced Thyroid Carcinoma
- Lead investigator
- Bo Wang,MD · Director, Head of Thyroid Surgery, Principal Investigator, Clinical Professor
- Hospital
- Fujian Medical University Union Hospital
- Status
- Not yet recruiting
- Registry
- NCT07010393
-
Study A Cross-sectional Study on Iodine Status and Characteristics of Papillary Thyroid Cancer
- Lead investigator
- Hai-qing Zhang · Chief physician
- Hospital
- Shandong Provincial Hospital
- Status
- Not yet recruiting
- Registry
- NCT06626581
This page only shares publicly registered study information. It does not recommend or encourage joining any study. Participation is entirely voluntary and the risks of an unapproved treatment are unknown; contact the hospital directly for eligibility and informed-consent details.
Hospitals with a national key specialty record
Show the hospital records 12 hospitals with a key-specialty record
Each row is a hospital with a national key clinical specialty record in a specialty this condition is filed under. This is a record of published listings, not a recommendation and not a ranking.
12 hospitals with a matching national key specialty record.
Values written in Chinese are quoted as published by the source.
Questions about this condition
We cannot give medical advice, but we can answer questions about this page and about arranging treatment in China.
ICD codes
Show the code table 1 ICD code
| Version | Code | Name in that version |
|---|---|---|
| ICD-10-WHO | C73 | Malignant neoplasm of thyroid gland |
Rows are the WHO ICD-10 entries for this condition, quoted as published.
Source & evidence
- Source URL
- https://wjw.fujian.gov.cn/xxgk/fgwj/zxwj/201904/P020190412506737868905.xlsx
- Source scheme
- https
- Source type
- Provincial health commission
- Evidence level
- A - said by a provincial health commission or university
- Retrieved on
- 2026-09-24